Comparing a new biosimilar to Opdivo for melanoma after surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether a new biosimilar drug (Bmab1700) works as well as the approved immunotherapy Opdivo (nivolumab) to prevent melanoma from coming back after surgery. You would receive either the biosimilar or Opdivo for about a year, and researchers will compare how your body handles the drug and its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your melanoma (skin cancer) was completely removed with surgery within the past 12 weeks.
- Your cancer was stage IIB, IIC, III, or IV (meaning it had spread to lymph nodes or nearby skin) before surgery.
- You have no active autoimmune disease and have not taken strong immune-suppressing drugs for one in the last 2 years.
- You have not had prior treatment with nivolumab, pembrolizumab, ipilimumab, or similar immunotherapies.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for 150 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a biosimilar drug (AVT32-DRL_PB) to see how it compares to the approved immunotherapy Keytruda® in people whose melanoma has been fully removed by surgery. It aims to help prevent the cancer from coming back.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial compares a new drug, MB11, to the standard treatment Opdivo for people with advanced melanoma that hasn't been treated yet. The goal is to see if MB11 works just as well.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.